210 related articles for article (PubMed ID: 36947281)
1. A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
Irino K; Jinnouchi F; Nakano S; Sawabe T
Clin Rheumatol; 2023 Jul; 42(7):1959-1963. PubMed ID: 36947281
[TBL] [Abstract][Full Text] [Related]
2. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
Sin JH; Zangardi ML
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
[TBL] [Abstract][Full Text] [Related]
5. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
[TBL] [Abstract][Full Text] [Related]
8. Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives.
He L; Yang C; Wang Y
Expert Opin Biol Ther; 2023; 23(10):1005-1013. PubMed ID: 37614018
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
Yan WL; Yang SL; Zhao FY; Xu XJ
J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
12. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
[TBL] [Abstract][Full Text] [Related]
13. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
[TBL] [Abstract][Full Text] [Related]
16. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.
Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D
Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
18. Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT.
Kobayashi R; Tanaka J; Hashino S; Ota S; Torimoto Y; Kakinoki Y; Yamamoto S; Kurosawa M; Hatakeyama N; Haseyama Y; Sakai H; Sato K; Fukuhara T
Bone Marrow Transplant; 2014 Feb; 49(2):254-7. PubMed ID: 24037021
[TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition.
Guild A; Fritch J; Patel S; Reinhardt A; Acquazzino M
Pediatr Rheumatol Online J; 2022 Nov; 20(1):104. PubMed ID: 36401314
[TBL] [Abstract][Full Text] [Related]
20. A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis.
Summerlin J; Wells DA; Anderson MK; Halford Z
Ann Pharmacother; 2023 Jul; 57(7):867-879. PubMed ID: 36349896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]